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Introduction {#sec005}
============

Although the rate of mortality owing to acute myocardial infarction (MI) has decreased considerably in recent years concomitant with the evolution of coronary reperfusion interventions, MI remains one of the leading causes of chronic heart failure (CHF) that occurs as a consequence of adverse left ventricular (LV) remodeling \[[@pone.0230392.ref001], [@pone.0230392.ref002]\]. In the past decade, there has been significant progress in regenerative therapies using different types of stem cells for suppressing adverse LV remodeling.

In the human body, there are several endogenous regenerative mechanisms that function in the repair of injured organs. Bone marrow-derived mesenchymal stem cells (BM-MSCs) or tissue stem cells play an important role in repairing damaged tissues \[[@pone.0230392.ref003], [@pone.0230392.ref004]\]. BM-MSCs, in particular, show a strong potential to repair damaged organs by recruiting other host cells, secreting different growth factors, or differentiating into various cells, such as endothelial cells \[[@pone.0230392.ref005]\], thereby promoting angiogenesis and inhibiting adverse fibrosis in various injuries and diseases including injured muscles \[[@pone.0230392.ref006]\], cerebral infarction \[[@pone.0230392.ref007]\], and MI \[[@pone.0230392.ref008], [@pone.0230392.ref009]\]. As an alternative to conventional cellular therapy, by enhancing endogenous repair mechanisms with stem cells or pharmacological agents, or by accelerating endogenous regenerative function, could offer a less invasive regenerative treatment.

High-mobility group box 1 protein (HMGB1), a non-histone nuclear protein regulating chromatin structure \[[@pone.0230392.ref010]\], has two different effects as follows: HMGB1 released from necrotic cells activates macrophages and neutrophils, thereby accelerating inflammation in injured tissues \[[@pone.0230392.ref010]\]; in contrast, HMGB1 is also a regenerative factor that enhances the mobilization of PDGFRα^+^ mesenchymal cells from the bone marrow to damaged tissue \[[@pone.0230392.ref011]--[@pone.0230392.ref013]\]. PDGFRα is a main marker of MSCs in bone marrow \[[@pone.0230392.ref014]\]. The inflammatory reactions elicited by HMGB1 are induced via binding between specific HMGB1 domains and Toll-like receptors-2/-4 or the receptor for advanced glycation end product \[[@pone.0230392.ref015], [@pone.0230392.ref016]\]. By resecting the previous reported functional domains of HMGB1 associated with inflammatory reactions, we have created a novel HMGB1 fragment ([Fig 1](#pone.0230392.g001){ref-type="fig"}). We previously determined that this HMGB1 fragment is associated with the inhibition of adverse ventricular remodeling \[[@pone.0230392.ref011]\].

![Schematic of the HMGB1 fragment.\
A novel domain of HMGB1 is associated with enhancing the mobilization of BM-MSCs (Red lines). Recombinant HMGB1 fragment has been created using this domain.](pone.0230392.g001){#pone.0230392.g001}

In the present study, we used a rat model of MI to test the hypothesis that systemic administration of this HMGB1 fragment promotes tissue regeneration by mobilizing BM-MSCs to the damaged heart tissue.

Materials and methods {#sec006}
=====================

Animal care {#sec007}
-----------

All experimental procedures and protocols were approved by the institutional ethics committee of Osaka University Graduate School of Medicine (approval number 28-024-02). Animal care was reviewed and approved by the National Institutes of Health Publication, "Guide for the Care and Use of Laboratory Animals". All animal procedures followed in the present study conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes \[[@pone.0230392.ref017]\]. All experimental animals were euthanized using sufficient isoflurane to minimize animal suffering.

Short length of HMGB1 fragment {#sec008}
------------------------------

As previously reported \[[@pone.0230392.ref011]\], the MSC mobilization domain from human HMGB1 was produced as "HMGB1 fragment" by solid-phase synthesis, which is shown in [Fig 1](#pone.0230392.g001){ref-type="fig"}. The HMGB1 fragment was provided by StemRIM (Osaka, Japan), and was dissolved in phosphate buffered saline (PBS) to a concentration of 1 mg/ml prior to systemic administration.

Examination 1: CHF after MI with administration of systemic HMGB1 fragment {#sec009}
--------------------------------------------------------------------------

For the study protocol of the first examination, seven-week-old male Sprague-Dawley rats (SD rats; 200--250 g, Oriental Yeast Co. ltd, Japan) underwent left thoracotomy under 1.5% isoflurane inhalation and mechanical ventilation using a volume-controlled ventilator \[[@pone.0230392.ref018]\]. The left coronary artery (LCA) was ligated with 6--0 polypropylene (C-1, ETHICON) at the level of the bottom edge of the left atrial appendage. At 2 weeks after LCA high ligation, rats were divided into two subgroups and received either HMGB1 (3 mL/kg/day; n = 14) or the same volume of PBS (3 mL/kg/day; n = 12) as a control by injection into the femoral veins for 4 consecutive days under 1.5% isoflurane inhalation via a nose cone. The dose of HMGB1 was based on our previous studies \[[@pone.0230392.ref011]--[@pone.0230392.ref013]\]. At 4 weeks after HMGB1 treatment, LV adverse remodeling was assessed using histological and real-time PCR (RT-PCR) analyses.

Examination 2: BM-MSC mobilizing factor in a rat model of MI {#sec010}
------------------------------------------------------------

To evaluate the homing factor of MSCs in the damaged heart tissue prior to HMGB1 treatment, the second examination was performed. We focused on stromal cell derived-factor-1 (SDF1), a well-known homing factor of MSCs \[[@pone.0230392.ref019], [@pone.0230392.ref020]\]. Using the MI model rat described above (n = 6), SDF1 expression at peri-infarction zone, ventricular septal zone, and remote zone was compared to those in normal rats of the same age (n = 10) by histological analysis and RT-PCR analysis. Histology of the peri-infarction area was investigated by evaluating vascular endothelial cells using electron microscopy.

Examination 3: Generation of green fluorescent protein-bone marrow transplantation (GFP-BMT) model {#sec011}
--------------------------------------------------------------------------------------------------

To investigate whether BM-MSCs would be mobilized from the bone marrow to the MI lesion, a third examination using the GFP^+^ BM transplantation (BMT) rat MI model was performed.

For the study protocol of the third examination, BM cells were isolated from 9- to 11-week old male Wistar (W)-Tg (CAG-GFP) 184Ys rats that ubiquitously expressing enhanced GFP (National BioResource Project-rat, Japan). Isolated GFP-BM cells (3×10^7^) were injected via the tail vein into five-week old male Wistar rats (CLEA Japan. Inc, Japan) that had received lethal irradiation of 10 Gy of X-rays \[[@pone.0230392.ref021]\]. Five weeks after GFP^+^ BM transplantation, LCA ligation was performed. Two weeks after LCA ligation, HMGB1 (n = 8) or PBS (n = 7) was administered for 4 consecutive days as in the first examination. Four weeks after each treatment, GFP expression in the peri-infarction area was evaluated in each group using RT-PCR analysis. The recruitment of GFP^+^ BM-MSCs to the damaged heart tissue was assessed using immuno-histological analysis. We also investigated the therapeutic effects of the recruited BM-MSCs associated with paracrine activity and differentiation into the vessel constituent cells using immuno-histological analysis.

Protocol of intra-vital imaging using two-photon microscopy {#sec012}
-----------------------------------------------------------

As significant recruitment of BM-MSCs to blood circulation was observed at 12 h after systemic HMGB1 injection in our previous study \[[@pone.0230392.ref012]\], intra-vital imaging was performed as previously described to evaluate the mobilization of BM-cells to damaged myocardium in real time \[[@pone.0230392.ref022]\]. The GFP^+^-BMT rat MI model was placed on a stainless plate under 1.5% isoflurane inhalation and mechanical ventilation using a volume-controlled ventilator. After general anesthesia, a central venous catheter (CVC) was inserted through the femoral vein. Thereafter, the chest wall was resected using bipolar scissors (Force FX-CS, E4051CT; Valleylab, Denver, USA), and the peri-infarction area of the beating heart was affixed by suction to the central aperture of an original stabilizer. The intra-vital microscope system comprised a two-photon microscope (A1-MP; Nikon, Japan) incorporating a laser (Chameleon Vision II Ti:Sapphire; Coherent, Santa Clara, CA, USA) tuned to 800--880 nm and an upright microscope equipped with a 25× water immersion objective lens (CFI Apo 25 × W MP; Nikon). An original plate-stabilizer setup was placed on two-axis translation stage under the objective lens in a temperature-controlled dark box. After adjusting the objective lens through the bioscope, the beating heart was viewed in vivo via the central aperture. Isolectin-B4 was injected via the CVC, and HMGB1 (n = 6) or PBS (n = 5) was injected at the same dose as used in the first examination. After each administration, continuous live imaging was performed over the subsequent 12 h. As in the third examination, the average number of GFP^+^/PDGFRα^+^ cells at the peri-infarction area was assessed using histological analysis.

Echocardiography {#sec013}
----------------

Cardiac functions were evaluated by echocardiogram using SONOS-7500 and s12-probe (89 Hz, PHILIPS, Netherlands) under 1.5% isoflurane inhalation through a nose cone. Left ventricular diastolic and systolic diameter (LVDd and LVDs) were obtained from parasternal short-axis views. Additionally, left ventricular ejection fraction (LVEF) was calculated from these diameters. In the first examination, these parameters were assessed before HMGB1 treatment, and were measured again at 1 and 4 weeks after HMGB1 treatment. In the third examination, LVEF was evaluated prior to HMGB1 treatment and remeasured at 4 weeks after HMGB1 treatment.

Histological analysis {#sec014}
---------------------

The heart was resected perpendicularly to the long axis of the left ventricle in slices of a few mm. All the excised heart specimens were fixed with 10% buffered formalin for paraffin-embedded sections or 4% paraformaldehyde for frozen sections for over a day.

In the first examination, paraffin-embedded sections were resected in 2-μm slices and stained with hematoxylin-eosin (HE) and picrosirius-red to evaluate the fibrotic area using light microscopy (Leica, Wetzlar, Germany). The paraffin-embedded sections were also stained with periodic acid-Schiff (PAS) to assess cardiomyocyte hypertrophy in each group. Using light microscopy with BZ-analysis software (Keyence, Tokyo, Japan), the short-axis diameter of myocytes was counted in 10 randomly selected fields, and the average number calculated. Neovascularization in the peri-infarction area was evaluated using rabbit anti-von Willebrand factor polyclonal antibody (1:200; Dako, Glostrup, Denmark). Using light microscopy with BZ-analysis software, the number of von Willebrand factor-positive cells in 10 randomly selected fields was counted, and the average number calculated. MSCs mobilization to the damaged myocardium was evaluated using double staining with mouse anti-CD90 monoclonal (1:100; Abcam, Cambridge, UK) and rabbit anti-PDGFRα polyclonal (1:100; Thermo Fisher Scientific, Waltham, USA) antibodies for each group. Ten different fields at the peri-infarction area were randomly selected, and CD90^+^/PDGFRα^+^ cells were counted using confocal laser microscopy (Olympus, FV1000-D IX81, Tokyo, Japan). In the second examination, the frozen sections in MI and normal rats were stained with rabbit anti-SDF1 polyclonal antibody (1:50; Abcam, Cambridge, UK), and were evaluated using the confocal laser microscopy. In the third examination, the frozen sections were stained with PDGFRα (1:100; Thermo Fisher Scientific, Waltham, USA). Ten different fields of the peri-infarction area were randomly selected in each group, and GFP^+^/PDGFRα^+^ cells were counted using confocal laser microscopy. The average number was calculated in each group. Paracrine activity of BM-MSCs was assessed with antibody staining for vascular endothelial growth factor A (VEGF-A: rabbit anti-VEGF-A polyclonal antibody, 1:100; Abcam, Cambridge UK). Differentiation of the recruited BM-MSCs was assessed with staining of vascular endothelial cells using isolectin-B4 Alexa Fluor^™^ 568 conjugate (1:200; Thermo Fisher Scientific, Waltham, USA), or pericytes with rabbit anti-NG2 polyclonal antibody (1:100; LifeSpan Biosciences, Washington, USA).

Real-time PCR analysis {#sec015}
----------------------

Real-time PCR was performed as previously described \[[@pone.0230392.ref011]\]. Total RNA was extracted from cardiac tissue (peri-infarction area, ventricular septum, and remote area) and reverse transcribed using TaqMan reverse transcription reagents (Applied Biosystems, Stockholm, Sweden). RT-PCR was performed on an ABI PRISM 7700 system (Applied Biosystems) using rat-specific primers for *VEGF-A*, *transforming growth factor-β (TGFβ)*, *interleukin (IL)-1β*, and *IL-6* (Assay ID: Rn01511601_m1, Rn00572010_m1, Rn00580432_m1, and Rn01410330_m1, respectively) in the first examination; for *SDF1* (Assay ID: Rn00573260_m1) in the second examination; and for *GFP* (Assay ID: Mr04097229_mr) in the third examination. Each cDNA sample was evaluated in duplicate. Expression of target genes was normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each sample. Relative gene expression was determined using the 2^−ΔΔC^~T~ method.

Statistical analysis {#sec016}
--------------------

All statistical analyses were performed using JMP Pro 13.0.0 (SAS Institute, Inc., Cary, NC, USA). All data were expressed as the mean ± standard deviation (SD). Between-group differences were compared using the Welch's t-test. A *P*-value (*P*) \< 0.05 was considered statistically significant.

Results {#sec017}
=======

Examination 1: Improvement of cardiac function after HMGB1 treatment {#sec018}
--------------------------------------------------------------------

Details of the first examination are listed in [Fig 2A](#pone.0230392.g002){ref-type="fig"}. Standard transthoracic echocardiogram was performed at 0, 1 and 4 weeks after each injection ([Fig 2B](#pone.0230392.g002){ref-type="fig"}). Regarding baseline level of LVEF (HMGB1 group vs. control; 42.25 ± 5.07% vs. 43.94 ± 4.89%, *P* = 0.40), LVDd (0.968 ± 0.105 vs. 1.013 ± 0.086 mm, *P* = 0.24), and LVDs (0.792 ± 0.103 vs. 0.820 ± 0.087 mm, *P* = 0.45), there were no significant differences between each group. LVEF showed greater improvement in the HMGB1 group than in the control at 1 week (45.61 ± 5.926% vs. 39.15 ± 4.908%, *P* = 0.0056), and 4 weeks (48.61 ± 5.51% vs. 33.93 ± 5.27%, *P* \< 0.0001) after each administration. LVDs was significantly smaller in the HMGB1 group than in the control at 1 week (0.803 ± 0.091 vs. 0.896 ± 0.110 mm, *P* = 0.027) and 4 weeks later (0.833 ± 0.0905 vs. 0.963 ± 0.095 mm, *P* = 0.0016). Consequently, all rats in each group survived.

![Evaluation results during the first examination.\
The first examination aimed to evaluate the regenerative effect of HMGB1 in a rat model of MI. A: Protocol of first examination. Two weeks after MI, the HMGB1 fragment was administered for 4 days. Four weeks after HMGB1 fragment treatment, histological analyses were performed. B: Echocardiogram revealed that LVEF was significantly higher in the HMGB1 group (n = 14) than in the control (n = 12), at 4 weeks after each treatment. LVDs was significantly shorter in the HMGB1 group than in the control. C-E: LV adverse remodeling in each group was assessed by histological analysis. Interstitial fibrosis was assessed by Picrosirius-red staining (C. representative photomicrographs, 40×, scale bar = 1 mm). Fibrosis was significantly attenuated in the HMGB1 group compared with that in the control. Cardiomyocyte hypertrophy was assessed by Periodic acid-Schiff staining (D. representative photomicrographs, 200×, scale bar = 50 μm). Myocyte size was significantly smaller in the HMGB1 group than in the control. Neovascularization using antihuman von Willebrand factor antibody (E. representative photomicrographs, 400×, scale bar = 50 μm). Capillary density was significantly greater in the HMGB1 group than in the control. F: Evaluation of the recruitment of CD90^+^/PDFGRα^+^ cells to the peri-infarction area (600×, scale bar = 50 μm). More CD90^+^/PDFGRα^+^ cells were present in the HMGB1 group than in the control. G: RT-PCR analysis was performed in both groups for the following cytokines: *VEGF-A*, *TGFβ*, *IL-1β*, and *IL-6*. *P* -values were calculated using the Welch's t-test. *P* \< 0.05\*, *P* \< 0.01\*\*.](pone.0230392.g002){#pone.0230392.g002}

Histological analysis concerning post-MI adverse LV remodeling {#sec019}
--------------------------------------------------------------

Upon histological analysis, interstitial fibrosis was significantly attenuated in the HMGB1 group as compared to the control (fibrotic area; 11.58 ± 5.18% vs. 23.07 ± 6.32%, *P* \< 0.0001; [Fig 2C](#pone.0230392.g002){ref-type="fig"}). For cardiomyocyte hypertrophy at the peri-infarction area, cardiomyocyte size was significantly smaller in the HMGB1 group than in the control (19.11 ± 2.59 vs. 26.82 ± 1.36 μm, *P* \< 0.0001, [Fig 2D](#pone.0230392.g002){ref-type="fig"}). Capillary density at the peri-infarction area was significantly greater in the HMGB1 group (1797.98 ± 271.85 vs. 959.04 ± 143.40/mm^2^, *P* \< 0.0001; [Fig 2E](#pone.0230392.g002){ref-type="fig"}) than in the control. In addition, comparison of the number of CD90^+^/PDFGRα^+^ cells at the peri-infarction area revealed that there were more CD90^+^/PDFGRα^+^ cells in the HMGB1 group than in the control (1636.84 ± 538.378 vs. 934.00 ± 250.236/mm^2^, *P* = 0.0003; [Fig 2F](#pone.0230392.g002){ref-type="fig"}).

Significant increase of VEGF and decrease of TGFβ in HMGB1 group {#sec020}
----------------------------------------------------------------

RT-PCR data for each cytokine expression are shown in [Fig 2G](#pone.0230392.g002){ref-type="fig"}. The level of *VEGF-A* mRNA expression in the peri-infarction area was significantly higher in the HMGB1 group than in the control (1.63 ± 0.64 vs. 1.18 ± 0.25, *P* = 0.029). At the septal zone, *VEGF-A* mRNA expression was also significantly higher in the HMGB1 group than in the control (1.14 ± 0.11 vs. 0.99 ± 0.13, *P* = 0.0040). The level of *TGFβ* mRNA expression in the peri-infarction area was significantly lower in the HMGB1 group (1.13 ± 0.25 vs. 1.66 ± 0.75, *P* = 0.037).

With respect to inflammatory cytokines, *IL-1β* mRNA expression at the septal zone was significantly lower in the HMGB1 group than in the control (0.51 ± 0.21 vs. 0.71 ± 0.24, *P* = 0.031). *IL-6* mRNA expression in the peri-infarction area was lower in the HMGB1 group (1.92 ± 1.02 vs. 3.61 ± 1.76, *P* = 0.0092) than in the control.

Examination 2: Significant increase of SDF1 expression at damaged heart tissue prior to HMGB1 treatment {#sec021}
-------------------------------------------------------------------------------------------------------

A second examination was performed to assess the expression of SDF1 in the damaged heart tissue prior to injection of the HMGB1 fragment ([Fig 3A](#pone.0230392.g003){ref-type="fig"}). The detailed results are shown in [Fig 3](#pone.0230392.g003){ref-type="fig"}. Confocal microscopy imaging showed SDF1 expression along the peri-infarction area in the MI rat. In contrast, there was no significant SDF1 expression in the normal rat ([Fig 3B](#pone.0230392.g003){ref-type="fig"}). RT-PCR analyses also showed that *SDF1* mRNA expression in the peri-infarction area was significantly higher in the MI rat than in the normal rat (MI model vs. normal; 2.17 ± 0.48 vs. 0.93 ± 0.16, *P* = 0.0010; [Fig 3C](#pone.0230392.g003){ref-type="fig"}). Further, *SDF1* mRNA expression in the border zone was the highest in all areas (septal zone; 1.96 ± 0.96 vs. 1.03 ± 0.25, *P* = 0.064, remote zone; 1.11 ± 0.24 vs. 0.93 ± 0.17; *P* = 0.22).

![SDF1 expression at the infarcted heart tissue in MI rats prior to HMGB1 treatment.\
The second examination was performed using the same MI rats prior to HMGB1 treatment to assess the expression of SDF1, a representative homing factor of MSCs. A: Study protocol of second examination. B: Histological analysis revealed SDF1 expression along the peri-infarction area in MI model and normal rats (40×, scale bar = 200 μm). C: RT-PCR analysis indicated that SDF1 expression increased significantly in MI rats (n = 6) compared with normal rats (n = 10). *P* -values were calculated using the Welch's t-test. *P* \< 0.05\*, *P* \< 0.01\*\*.](pone.0230392.g003){#pone.0230392.g003}

In electron microscopic analyses of the peri-infarction area, tight junctions between vascular endothelial cells were unclear in MI rats ([Fig 4A](#pone.0230392.g004){ref-type="fig"}), and some of the cell-cell junctions were completely destroyed ([Fig 4B](#pone.0230392.g004){ref-type="fig"}). In contrast, they were clearly observed in normal rats ([Fig 4C and 4D](#pone.0230392.g004){ref-type="fig"}).

![Electron microscopy analysis of the peri-infarction area prior to HMGB1 treatment.\
Representative electron microscopy images (2000×, 6000×, 30000×) of the cell-cell junctions between each vascular endothelial cell in MI rats (A, B) and normal rats (C, D). Whereas those of normal rats were clearly observed (yellow arrows). A: Tight junctions between each vascular endothelial cell are unclear in MI rats (white arrows). B: In the peri-infarction area, some of the cell-cell junctions are destroyed and detached (white arrows). C, D: Electron microscopy analysis of a normal rat heart. The tight junctions between each vascular endothelial cell are clearly observed (red arrows).](pone.0230392.g004){#pone.0230392.g004}

Examination 3: Detection of BM-MSC mobilization to damaged heart tissue by HMGB1 in GFP-BMT model {#sec022}
-------------------------------------------------------------------------------------------------

To investigate whether MSCs could mobilize from the bone marrow to the damaged heart tissue after HMGB1 treatment, a third examination was performed with GFP^+^ bone marrow transplanted (GFP-BMT) rat MI model ([Fig 5A](#pone.0230392.g005){ref-type="fig"}). At 4 weeks after each treatment, a greater improvement in LVEF was observed in the HMGB1 group than in the control, similar to the first examination (49.30 ± 3.75 vs. 36.52 ± 3.09%, *P* \< 0.0001; [Fig 5B](#pone.0230392.g005){ref-type="fig"}). In RT-PCR analyses, the level of *GFP* mRNA at the peri-infarction area was found to be significantly higher in the HMGB1 group than in the control (1.76 ± 0.49 vs. 0.93 ± 0.17, *P* = 0.017; [Fig 5C](#pone.0230392.g005){ref-type="fig"}). Histological analyses also revealed the recruitment of GFP^+^ cells along the peri-infarction area in the HMGB1 group ([Fig 5D--1](#pone.0230392.g005){ref-type="fig"}). Subsequently, we also evaluated GFP^+^/PDGFRα^+^ cells in the peri-infarction area and found a significant increase of GFP^+^/PDGFRα^+^ cells in the HMGB1 group compared with control (1418.70 ± 243.66 vs. 589.79 ± 66.52/mm^2^, *P* \< 0.0001; [Fig 5D--2](#pone.0230392.g005){ref-type="fig"}). In accord, VEGF paracrine activity of the recruited BM-MSCs was significantly increased after treatment with the HMGB1 fragment in the first examination.

![Third examination using a green fluorescent protein bone marrow transplantation (GFP-BMT) rat model.\
To investigate whether BM-MSCs were mobilized to the damaged myocardium after HMGB1 injection, a third examination using GFP-bone marrow transplantation (BMT) model rats was performed similarly to the first examination. A: Study protocol of the third examination. B: LVEF shows a significant improvement in the HMGB1 group (n = 8) compared to control (n = 7) after 4 weeks. C: On RT-PCR analysis, GFP expression in the border zone was significantly higher in the HMGB1 group than in the control. D: 1) Representative photomicrographs of the peri-infarction area after each treatment (100×, scale bar = 100 μm). Border lines are shown as yellow dotted lines. 2) Representative photomicrographs of PDGFRα staining (600×, scale bar = 50 μm). A larger number of GFP^+^/PDGFRα^+^ is observed in the HMGB1 group than in the control group. *P* -values were calculated using the Welch's t-test. *P* \< 0.05\*, *P* \< 0.01\*\*.](pone.0230392.g005){#pone.0230392.g005}

In the HMGB1 group, confocal microscopic imaging showed VEGF-A expression around GFP^+^/PDGFRα^+^ cells at the peri-infarction area. In contrast, VEGF-A expression at the border zone was unclear in the control group ([Fig 6A](#pone.0230392.g006){ref-type="fig"}). To assess differentiation of the recruited BM-MSCs in the damaged heart tissue, we performed IL-B4 staining and found that some GFP^+^/PDGFRα^+^ cells also stained positive for IL-B4. Moreover, some GFP^+^/PDGFRα^+^/IL-B4^+^ cells were present in the vessel at the border zone ([Fig 6B](#pone.0230392.g006){ref-type="fig"}). In addition, some GFP^+^/PDGFRα^+^/NG-2^+^ cells also formed part of the vessel in the peri-infarction area ([Fig 6C](#pone.0230392.g006){ref-type="fig"}). No GFP^+^ cardiomyocytes were detected in the present study.

![Paracrine activity and differentiation of the recruited BM-MSCs in the damaged heart tissue.\
A: Confocal laser microscopy analysis revealed VEGF-A expression around the GFP^+^/PDGFRα^+^ cells (200×, scale bar = 100 μm). Each white dotted line depicts the border. B, C: Histological analysis of GFP^+^/PDGFRα^+^ cells differentiating to vessel constituent cells in the peri-infarction area. In the HMGB1 group, some GFP^+^/PDGFRα^+^ cells stained with anti-isolectin-B4 (B. 1000×, scale bar = 50 μm) or anti-NG-2 (C. 600×, scale bar = 50 μm) antibodies were observed in a subset of vessels within the peri-infarction area (yellow arrows).](pone.0230392.g006){#pone.0230392.g006}

Real time intravital imaging was performed to evaluate GFP^+^-cells recruitment to damaged myocardium ([Fig 7A](#pone.0230392.g007){ref-type="fig"}). The continuous live imaging analyses revealed that GFP^+^ BM-cells gradually increased after injection with the HMGB1 fragment (Video 1). In contrast, the recruitment of GFP^+^ BM-cells was not enhanced after PBS injection. At 12 h post-injection with the HMGB1 fragment or PBS, more GFP^+^/PDGFRα^+^ cells were visualized in the HMGB1 group than in the control group by histological analyses (1516.5 ± 132.5 vs. 689.9 ± 70.6/mm^2^, *P* \< 0.001; [Fig 7B](#pone.0230392.g007){ref-type="fig"}). Additionally, those GFP^+^-cells were recruited along the border zone with SDF1 over-expression ([Fig 7C](#pone.0230392.g007){ref-type="fig"}). In contrast, significant recruitment of GFP^+^ BM-cells was not observed at the remote area where significant expression of SDF1 was not observed.

![Intravital imaging of GFP-BMT rat MI model after HMGB1 treatment.\
Intravital imaging analysis was performed using the GFP-BMT rat MI model to visualize HMGB1-induced GFP^+^-cells mobilization to the damaged heart tissue in real time. A: Details of the study protocol using intravital imaging. B: Histological findings in GFP-BMT rat MI model 12 h after HMGB1 treatment. 1, 2) More GFP^+^/PDGFRα^+^ cells were visualized in the HMGB1 group compared with the control (100×, 600×; scale bar = 100, 200 μm, respectively). C: In the HMGB1 group, GFP^+^-cells were recruited along the peri-infarction area with SDF1 over-expression (100×, scale bar = 200 μm). Conversely, the recruitment of GFP^+^-cells was not enhanced at the remote area, where significant expression of SDF1 was not observed. *P* -values were calculated using the Welch's t-test. *P* \< 0.01\*\*.](pone.0230392.g007){#pone.0230392.g007}

Discussion {#sec023}
==========

In the first examination, we demonstrated that systemic administration of HMGB1 fragment could inhibit adverse LV remodeling by inducing angiogenesis and reducing fibrosis, leading to an improvement of LVEF. The first examination also showed that the number of MSCs at the damaged heart tissue site was significantly increased in after treatment with the HMGB1 fragment. In the second examination, we investigated the homing factor of MSCs in the damaged myocardium. Our results confirmed the significant expression of SDF1 around the peri-infarction area prior to systemic administration of HMGB1 fragment. The third examination using the GFP-BMT rat MI model showed that the recruitment of PDGFRα^+^/CD90^+^-BM cells to the peri-infarction area was further enhanced by the HMGB1 fragment. Moreover, confocal microscopic imaging revealed that the PDGFRα^+^ BM-cells might release growth factors such as VEGF, and that some might have differentiated into vessel constituent cells at the damaged myocardium.

We investigated the mechanisms through which BM-derived mesenchymal cells including BM-MSCs are recruited to the infarcted myocardium in response to HMGB1 fragment administration. In this regard, we have previously reported that HMGB1 promotes PDGFRα^+^ BM-MSCs aggregation around blood vessels in the bone marrow and that those BM-MSCs migrate via the circulatory system \[[@pone.0230392.ref012]\]. In another previous study, we have demonstrated that HMGB1 can induce the expression of C-X-C chemokine receptor 4 (CXCR4) on the surface of recruited BM-MSCs, both *in vivo* and *in vitro* \[[@pone.0230392.ref013]\]. The ligand of CXCR4 is SDF1, which plays an important role in the migration and proliferation of various stem cells, including BM-MSCs \[[@pone.0230392.ref019], [@pone.0230392.ref020]\].

In the present study, we revealed that SDF1 expression was significantly increased in MI rats, particularly in the peri-infarction area ([Fig 3B and 3C](#pone.0230392.g003){ref-type="fig"}), consistent with the findings of previous studies that showed that SDF1 expression increases in ischemic lesions, such as the microenvironment of tumors where fibroblasts, epithelial cells, or endothelial cells secrete SDF1 \[[@pone.0230392.ref019], [@pone.0230392.ref020], [@pone.0230392.ref023]\]. Given these findings, BM-MSCs might be mobilized to the peri-infarction area via CXCR4/SDF1 signaling complex ([Fig 8](#pone.0230392.g008){ref-type="fig"}). In our present study, the cell-cell junctions of vascular endothelial cells in the peri-infarction area were weakened. Theoretically, it is possible that BM-MSCs adhere to the walls of vessel in the border zone via CXCR4/SDF1 signaling, and accordingly migrate from the vessels to the ECM via the gaps between vascular endothelial cells ([Fig 4](#pone.0230392.g004){ref-type="fig"}).

![Schematic outline of the present study.\
Systemic administration of HMGB1 fragment can mobilize BM mesenchymal cells, including BM-MSCs, to blood circulation. Consequently, these BM-derived mesenchymal cells accumulate in the damaged myocardium through the SDF1/CXCR4 signaling complex, leading to functional recovery by paracrine activity of the BM-MSCs or to differentiation of some vascular constituent cells.](pone.0230392.g008){#pone.0230392.g008}

We also investigated the mechanisms by which systemic injection of HMGB1 fragment inhibits adverse LV remodeling. We considered that several factors could be associated with the regenerative effects of the HMGB1 fragment. Similar to our study, several in vivo studies using HMGB1 have showed that HMGB1 can induce angiogenesis through VEGF in ischemic tissue, such as peripheral artery disease and acute MI \[[@pone.0230392.ref024]--[@pone.0230392.ref026]\]. Indeed, in the present study, a significant increase in *VEGF-A* expression was found in the peri-infarction area of the HMGB1 group as compared with the control ([Fig 2G](#pone.0230392.g002){ref-type="fig"}). The present study also revealed the overexpression of VEGF-A around the recruited BM-MSCs at the peri-infarction area ([Fig 6A](#pone.0230392.g006){ref-type="fig"}). Given these findings, we hypothesized that the HMGB1 fragment induced PDGFRα^+^ BM-cells, which secreted various growth factors such as VEGF in the damaged myocardium. We also hypothesized that paracrine activity of the recruited BM-MSCs could contribute to the therapeutic effects of HMGB1 fragment, as it has been reported that the regenerative effects of cell-based therapies using various stem cells can be attributed to paracrine activity \[[@pone.0230392.ref027]--[@pone.0230392.ref031]\]. This study also suggested that the recruited GFP^+^/PDGFRα^+^cells may have differentiated into vessel constituent cells, such as vascular endothelial cells or pericytes, in the peri-infarcted area ([Fig 6B and 6C](#pone.0230392.g006){ref-type="fig"}). Differentiation of the recruited BM-MSCs may be a crucial factor associated with the regenerative effects of the HMGB1 fragment. Indeed, numerous *in vitro* and *in vivo* studies have revealed that BM-MSCs have the potential to differentiate into endothelial cells, pericytes, and smooth muscle cells \[[@pone.0230392.ref005], [@pone.0230392.ref032]\]. It is also conceivable that HMGB1 itself might have a regenerative effect in adverse LV remodeling. Takahashi and colleagues have reported that direct injection of HMGB1 into the myocardium can attenuate local myocardial inflammation, leading to the inhibition of cardiomyocyte hypertrophy and expansion of fibrosis \[[@pone.0230392.ref033]\]. With respect to adverse effect of full-length HMGB1 as inflammation mediator, the present study showed that the inflammatory activity in heart tissue might have been attenuated in MI rats treated by the HMGB1 fragment, given that we observed significant decreases in IL-1β and IL-6 levels after HMGB1 treatment ([Fig 2G](#pone.0230392.g002){ref-type="fig"}). Results from our previous study have demonstrated that CD68^+^ inflammatory cells in the heart tissue of a hamster model of dilated cardiomyopathy are significantly decreased in the HMGB1 treated group compared with control group \[[@pone.0230392.ref011]\], which suggests that the HMGB1 fragment could not enhance inflammation compared with the full-length HMGB1 ([Fig 1](#pone.0230392.g001){ref-type="fig"}).

There are essentially two types of cardiac regenerative therapy for ischemic cardiomyopathy (ICM), cell-based regenerative therapy (CBRT) \[[@pone.0230392.ref027]\] and endogenous regenerative therapy (ERT) \[[@pone.0230392.ref025], [@pone.0230392.ref026]\]. To date, CBRT has been the mainstream approach, and numerous studies have reported its usefulness with different types of stem cells \[[@pone.0230392.ref030], [@pone.0230392.ref031]\], including MSCs \[[@pone.0230392.ref008], [@pone.0230392.ref009]\]. CBRT requires an in-house cell-processing center with an aseptic environment in the hospital \[[@pone.0230392.ref034]\]. Because drug-induced regenerative therapy does not require any cell culture, the quality of those cells is more easily maintained than with CBRT. An additional limitation of CBRT is that these stem cells are usually introduced via several invasive delivery methods, including intra-coronary and intra-myocardial administration, and cellular sheet implantation \[[@pone.0230392.ref027]--[@pone.0230392.ref030]\]. In contrast, ERT with HMGB1 administration does not require those invasive procedures. Further clarification of the mechanism of CBRT would facilitate progress in regenerative drug discovery, thereby increasing the possibility of ERT offering a minimally invasive therapy for patients with ICM in the future.

This study should be carefully interpreted because of limitations such as the relatively small number of MI rats, especially in the second examination using the GFP-BMT rat MI model. The angiogenesis mechanism through VEGF-A by the recruited BM-MSCs should be further investigated. Because VEGF-A plays an important role in angiogenesis of HMGB1 as shown in our study and in previous reports \[[@pone.0230392.ref024]--[@pone.0230392.ref026]\], it would be useful to evaluate a model with blocked VEGF pathway to determine whether this increase has a causal role in documented angiogenesis. With respect to the mobilized BM-MSCs differentiation into the endothelial cells or pericytes, it is unclear whether GFP^+^/PDGFRα^+^ and IL-B4 or NG2 are co-expressed because PDGFRα seems to be more highly expressed in the vessels, although other cells also seem to be slightly stained in red. To determine more precisely that the recruited BM-MSCs can differentiate into these vessel constituent cells, more analyses will be required.

Moreover, the present study showed the regenerative effects of the HMGB1 fragment for MI in rats. To translate our results for application in the clinical setting, pre-clinical studies with larger animal models such as the porcine model of MI are required.

Conclusion {#sec024}
==========

Systemic administration of the HMGB1 fragment induces angiogenesis and reduces fibrosis by mobilizing BM-MSCs to the peri-infarction area, thereby providing a potential new approach for the treatment of ICM with CHF.

Supporting information {#sec025}
======================

###### Intravital imaging in the GFP-bone marrow transplantation model.

Videos of the intravital imaging analysis performed in GFP-BMT rat MI model. Continuous intravital imaging with fixed view (0--12 h, 250×) showed that GFP^+^-BM cells gradually accumulated in the damaged heart tissue after HMGB1 treatment.

(MP4)

###### 

Click here for additional data file.

###### Histological analysis of CD90^+^/PDGFRα^+^ cells 4 weeks after HMGB1 treatment.

CD90^+^/PDGFRα^+^ and DAPI^+^ cells were counted as MSCs (A: 600×, scale bar = 50 μm, white arrows). Cells negative for CD90, PDGFRα, or DAPI were excluded (B: 600×, scale bar = 50 μm).

(TIFF)

###### 

Click here for additional data file.

###### All data of statistical analysis in the present study Examination 1.

(DOCX)

###### 

Click here for additional data file.
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Dear Dr. Takasumi Goto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, the reviewers raised criticisms concerning the quality of the images and asked for more detailed methods. Further, they also raised doubts on the induction of angiogenesis in the model.

We would appreciate receiving your revised manuscript by 3 months. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Federica Limana

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. The authors found that HMGB1 induces angiogenesis in vivo. This has already been demonstrated in several works (which have not been mentioned, e.g.: Int J Cardiol. 2017 Dec 15;249:349-356 - Diabetes. 2010 Jun;59(6):1496-505 - J Mol Cell Cardiol. 2008 Apr;44(4):683-93). The additional data is interesting, but it cannot disregard what has already been documented.

2\. The increase in VEGF could be an epiphenomenon. It would be useful to use a blocking model of the VEGF pathway (monoclonal antibodies, viral vectors, etc.) to verify whether this increase has a causal role in documented angiogenesis.

3\. How can it be demonstrated that the injection of cells does not induce an inflammatory response, which alone is responsible for the increase in VEGF?

Reviewer \#2: The ms by Takasumo Goto et al describe an interesting scenario, where administration of a short fragment of HMBG1 can help the recovery process after myocardial infarction. If the recruitment of PDGFRa+ cells from the bone marrow can be enhanced it can be of clinical relevance. However, the present manuscript is not ready for publication as it stands now. Major comments are that the whole manuscript is a bit unorganized, and the presented images are too small and at too low magnification to fully support the conclusions that the authors claim.

Specific comments:

It should be clear already in the abstract that it is a fragment of HMGB1 that is administered. Why is only the fragment (and not the full length protein administered)? Do they have different function or efficiency? This information should be presented already in the introduction.

The whole section on Material and methods would benefit from being re-written. As it is now, it is a mix of different sections -- some describing specific methods and other describing the setup of the different experiments. It is confusing to read and also some information is missing. Explain better the procedures of the heart tissue, from fixation to image analysis. How long time was the hearts fixed in 10% formalin before immunohistochemistry? How were the hearts sectioned, and how thick sections?

Explain better how mRNA was measured. It is not enough to write "At the peri-infarction area, the level of GFP mRNA (Applied Biosystems) was evaluated" as in page 11, line 11.

Describe how the cardiomyocyte size were measured.

Clarify how the the different examinations are numbered. The text says number 1,2,3 and the figures say 1, 1-2 ,2 and 2-2.

Page 8-9:

Clarify at what age the evaluation of cardiac function was assessed. First it is written that it is done 2 weeks after ligation, and later it says 1 and 4 weeks after administration.

The study protocols (Fig. 2A, 3A, 4A, 5A) are nice, but they can be improved with better time line.

Page 13

Specify what primers were used for RT-PCR for the different genes. Occasionally, it says QT-PCR in the text...

Page 21, line 12

If there is no significant difference, it is wrong to say that LVDd is smaller. The sentence should be rephrased, eg. "There was no difference in LVDd between the HMGB1 group and the control group." Also change in the figure legend.

The same goes for example TGFb, in Fig 2G.

Define which VEGF ligand that was analysed-- both with RT-PCR and immunohistochemistry.

Results:

Fig.2

How many times was HMBG1 injected? In material&methods it says 1 time, but in Fig2A it looks as 4 injections are performed.

Fig. 2F

Include images in higher magnification to show the morphology of the CD90+/Pdgfra+ cells. In these images the colored pixels are irregular in shape and it seems as CD90 and PDGFRa in some cases show exactly the same shape. Is this expected?

Please, give an example in a photo what colored pixels that were counted as cells and which that were not.

Fig. 3D

How representative are the images with weakened cell-cell junctions? Can this be quantified? Have you tried to perform immunohistochemistry for any tight-junction markers?

Fig. 4D-1 Chose another color than white for the dotted lines in this image.

Several images are very small and with low magnification. It is difficult to interpret the individual cells. For example in Fig. 4D-2; Fig4E

Fig. 4D-2 show that not all GFP+ cells express Pdgfra. What kind of cells are GFP+/Pdgfra-?

Fig. 4F, G

It is not clear that GFP/PDGFRa and isolection/NG2 are coexpressed in certain cells, as none of the stainings are very specific. For example, the red color is more or less present I all cells. It is interesting to speculate that the cells differentiate into pericytes or endothelial cell, but more analyses are needed.

Video

Were the two samples identical from start, which they should have been. The HMBG1-sample has much more green cells both circulating and in the tissue when the video starts, compared to the sample that gets PBS.

Discussion

Page 31, line 3

A higher density of vessels was shown in the HMBG1 group, but it has not been shown that HMBG1 induce angiogenesis.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Responses to the Reviewers' Comments

Review Comments to the Author

Reviewer 1:

Comment 1. The authors found that HMGB1 induces angiogenesis in vivo. This has already been demonstrated in several works (which have not been mentioned, e.g.: Int J Cardiol. 2017 Dec 15;249:349-356 - Diabetes. 2010 Jun;59(6):1496-505 - J Mol Cell Cardiol. 2008 Apr;44(4):683-93). The additional data is interesting, but it cannot disregard what has already been documented.

Response 1: Thank you for your comments. As you mentioned, the angiogenetic ability of HMGB1 in ischemic tissue has already been reported. In those studies, HMGB1 treatment has been shown to induce VEGF over-expression in ischemic tissue, similar to the results in our present study, leading to neovascularization in the damaged tissue. In the present study, we also showed that HMGB1 can recruit PDGFRα+ mesenchymal stem cells (MSCs) from the bone marrow to the ischemic heart tissue, and that these recruited cells may release several therapeutic cytokines such as VEGF and can lead to angiogenesis. We added the references you mentioned related to the angiogenetic ability of HMGB1 to the revised Discussion section and the reference list (page 29, lines 11-14; page 39, lines 16-17; and page 40, lines 1-7).

Comment 2. The increase in VEGF could be an epiphenomenon. It would be useful to use a blocking model of the VEGF pathway (monoclonal antibodies, viral vectors, etc.) to verify whether this increase has a causal role in documented angiogenesis.

Response 2: Compared with control, VEGF expression in the HMGB1 group was significantly increased at the peri-infarction area where BM-MSCs were significantly mobilized. Several in vivo and in vitro studies have reported that BM-MSCs have the potential to release many therapeutic cytokines such as VEGF. However, as you mentioned, the increase in VEGF could be an epiphenomenon following myocardial infarction. We think that additional examination using a model of blocked VEGF pathway will be required to clarify the underlying mechanism by which the recruited BM-MSCs induce angiogenesis through VEGF. We added this information as a limitation of the present study to the revised manuscript (page 32, lines 4-8).

Comment 3: How can it be demonstrated that the injection of cells does not induce an inflammatory response, which alone is responsible for the increase in VEGF?

Response 3: In the present study, we administrated the HMGB1 fragment to MI model rats. The HMGB1 fragment is a peptide. In the first examination, mRNA levels of IL-1β and IL-6, which are representative inflammatory cytokines, were significantly higher in the control group than those in the HMGB1-treated group. In addition, in our previous study, we have reported that CD68+ inflammatory cells in the heart tissue of a hamster model of dilated cardiomyopathy are significantly decreased in the HMGB1-treated group compared with that in the control. Given these findings, the HMGB1 fragment could not enhance local inflammation in the damaged heart tissue. We added this discussion associated with inflammatory reaction after HMGB1 treatment to the revised Discussion section (page 30, lines 15-17; and page 31, lines 1-5).

Reviewer 2:

The ms by Takasumo Goto et al describe an interesting scenario, where administration of a short fragment of HMBG1 can help the recovery process after myocardial infarction. If the recruitment of PDGFRa+ cells from the bone marrow can be enhanced it can be of clinical relevance. However, the present manuscript is not ready for publication as it stands now. Major comments are that the whole manuscript is a bit unorganized, and the presented images are too small and at too low magnification to fully support the conclusions that the authors claim.

Specific comments:

Comment 1: It should be clear already in the abstract that it is a fragment of HMGB1 that is administered. Why is only the fragment (and not the full length protein administered)? Do they have different function or efficiency? This information should be presented already in the introduction.

Response 1:

Thank you for all your comments. It is well known that full-length HMGB1 has two different effects. First, the inflammatory reaction. In acute inflammation, HMGB1 works as mediator of inflammation. Previous studies have already shown that the TLR-2, -4, or RAGE-binding domains of HMGB1 are associated with systemic inflammation.

On the other hand, HMGB1 is reportedly also a regenerative factor to repair damaged tissue. Our previous studies have shown that HMGB1 mobilizes CXCR4+-BM-MSCs from the bone marrow to the damaged skin. We also demonstrated that the recruited BM-MSCs promote skin repair, and that some BM-MSCs can differentiate into skin constituent cells.

Inflammatory reaction can enhance adverse remodeling in various heart diseases. Focusing on this regenerative effect of HMGB1, we removed the HMGB1 domains described as being related to systemic inflammation. Thus, the fragment of HMGB1 was obtained. In our previous study using a hamster DCM model, we found that this HMGB1 fragment inhibits fibrosis relative to the control. In addition, we have reported that CD68+ inflammatory cells in the heart tissue of the DCM model are significantly decreased in the HMGB1-treated group compared with that in the control.

Similar to our previous studies, our present study demonstrates that this HMGB1 fragment inhibits post-MI adverse remodeling such as fibrosis and cardiomyocyte hypertrophy, and that it does not enhance the inflammatory activity in the damaged heart tissue. We added this information to the revised manuscript (page 6, lines 6-11).

Comment 2: The whole section on Material and methods would benefit from being re-written. (a) As it is now, it is a mix of different sections -- some describing specific methods and other describing the setup of the different experiments. It is confusing to read and also some information is missing. (b) Explain better the procedures of the heart tissue, from fixation to image analysis. (c) How long time was the hearts fixed in 10% formalin before immunohistochemistry? (d) How were the hearts sectioned, and how thick sections?

\(e\) Explain better how mRNA was measured. It is not enough to write "At the peri-infarction area, the level of GFP mRNA (Applied Biosystems) was evaluated" as in page 11, line 11.

\(f\) Describe how the cardiomyocyte size were measured.

Response 2: Thank you for your comments concerning the Material and methods section. As you pointed out, we felt that this section would be a little confusing to read because some information overlapped with study protocols and each analysis.

\(a\) Regarding the Material and methods section, we changed the order of paragraphs as follows: Animal care, Short length of HMGB1 fragment, Study protocol of each examination (Examination 1-3, Intravital imaging), Echocardiography, Histological analysis, Real-time (RT) PCR analysis, and Statistical analysis (page 7, line 1, to page 15, line 7).

\(b\) In the revised Histological analysis subsection, we explain the fixation of the heart sample, and subsequently mentioned how to evaluate each histological image in each examination (page 12, line 8, to page 14, line 6).

\(c\) All the excised heart samples were fixed with 10% buffered formalin for paraffin-embedded sections or with 4% paraformaldehyde for frozen sections for over a day. We mention this in the revised Histological analysis subsection (page 12, lines 10-12).

\(d\) The heart was resected perpendicularly to the long axis of the left ventricle in slices measuring a few mm. We added this information to the revised Histological analysis subsection (page 12, lines 9-10).

\(e\) We modified the study protocol of examination 3 and excluded the GFP primer information from the protocol. Instead, we added the information on GFP primers to the revised RT-PCR analysis subsection, following your suggestion (page 14, lines 13-15).

\(f\) The paraffin-embedded sections were stained with periodic acid-Schiff to assess cardiomyocyte hypertrophy in each group. Using light microscopy, the short-axis diameter of myocytes was counted in 10 randomly selected fields, and the average number was calculated. We added how cardiomyocyte hypertrophy was assessed to the revised Histological analysis subsection (page 12, lines 15-17; and page 13, lines 1-2).

Comment 3: Clarify how the different examinations are numbered. The text says number 1,2,3 and the figures say 1, 1-2 ,2 and 2-2.

Response 3: I apologize for the wrong numbering of examinations in the submitted Figures. The numbering of examinations in the main text is correct. Examination 1 was aimed at evaluating the regenerative effects of HMGB1 in an MI model rat. In examination 2, we investigated SDF1 expression, which is a representative homing factor of BM-MSCs, in the damaged heart tissue prior to HMGB1 treatment. Examination 3 was performed to clarify the enhanced mobilization of BM-MSCs to the damaged heart tissue after HMGB1 treatment using a GFP-bone marrow transplantation (GFP-BMT) rat MI model. Additionally, intravital imaging analysis with the same GFP-BMT rat MI model was performed to investigate the recruitment of BM cells to damaged heart tissue after HMGB1 treatment in real time. We corrected the numbering of examinations in the revised manuscript (new Figures 2, 3, 5, and 7).

Comment 4: Page 8-9: Clarify at what age the evaluation of cardiac function was assessed. First it is written that it is done 2 weeks after ligation, and later it says 1 and 4 weeks after administration. The study protocols (Fig. 2A, 3A, 4A, 5A) are nice, but they can be improved with better time line.

Response 4: In all examinations of the present study, we used MI model rats 2 weeks after ligation of the left coronary artery. In examination 1, we administered HMGB1 to these MI model rats. We evaluated cardiac function in each group before HMGB1 or PBS administration, and reassessed cardiac function at 1 and 4 weeks after HMGB1 injection. We modified this section in the revised manuscript (page 12, lines 3-5). Additionally, as you suggested, we added a timeline in each figure (new Figure 2A, 3A. 5A, and 7A).

Comment 5: Page 13: Specify what primers were used for RT-PCR for the different genes. Occasionally, it says QT-PCR in the text...

Response 5: We have added the assay IDs for all the primers used in the present study (page 14, lines 11-14). We performed real-time PCR (RT-PCR) analysis in the present study. We changed \"QT-PCR\" to \"RT-PCR\" in the revised manuscript.

Comment 6: Page 21, line 12: If there is no significant difference, it is wrong to say that LVDd is smaller. The sentence should be rephrased, eg. "There was no difference in LVDd between the HMGB1 group and the control group." Also change in the figure legend. The same goes for example TGFb, in Fig 2G.

Response 6: As you mentioned, we considered that any result with p-values over 0.05 should not be mentioned as being higher or lower compared with the control. We therefore excluded the following sentences from the revised manuscript and figure legends:

・LVDd was smaller in the HMGB1 group, but not significantly different.

・LVDd was shorter in the HMGB1 group than in the control, but not significantly.

・ \...whereas that of the septal area was lower in the HMGB1 group, although the difference was not significant (0.76 ± 0.12 vs. 0.83 ± 0.22, P = 0.37).

Comment 7: Define which VEGF ligand that was analysed-- both with RT-PCR and immunohistochemistry.

Response 7: In both RT-PCR and immuno-histological analyses, the VEGF ligand was VEGF-A. We revised this point.

Comment 8: Fig.2

How many times was HMBG1 injected? In material & methods it says 1 time, but in Fig2A it looks as 4 injections are performed.

Response 8:

We apologize for the lack of this information in the submitted manuscript. Referring to our previous protocol, in examinations 1 and 3, HMGB1 (3 mg/kg/day) was administered for 4 days. We added this information to the revised manuscript (page 8, lines 11-14, and page 10, line 3).

Comment 9: Fig. 2F Include images in higher magnification to show the morphology of the CD90+/Pdgfra+ cells. In these images the colored pixels are irregular in shape and it seems as CD90 and PDGFRa in some cases show exactly the same shape. Is this expected?

Please, give an example in a photo what colored pixels that were counted as cells and which that were not.

Response 9: In the first examination, we counted CD90+/PDGFRα+/DAPI+ cells as MSCs, and we excluded cells that were negative for CD90, PDGFRα, or DAPI.

As you mentioned, the submitted figures were slightly unclear; therefore, we changed Figure 2F from the previous image at 400× magnification to a clearer image at 600× to improve the resolution (New Figure 2F). Furthermore, we have added Supplemental Figure 1, which is a representative photo showing which colored pixels were counted as CD90+/PDGFRα+ cells and which were not (Supplemental Figure 1).

Comment 10: Fig. 3D

How representative are the images with weakened cell-cell junctions? Can this be quantified? Have you tried to perform immunohistochemistry for any tight-junction markers?

Response 10: In the infarcted myocardium, many cell-cell junctions in endovascular cells were weakened, with tight junctions unclear in the lesion (new Figure 4A). Furthermore, some of them were completely disrupted (New Figure 4B). In contrast, in normal heart tissue, tight junctions between individual endothelial cells were more clearly observed compared with that in the damaged heart tissue (new Figure 4C, 4D). However, quantifying the damage to cell-cell junctions was difficult.

As you mentioned, prior to the above electron microscopy analysis, we evaluated the expression of VE-cadherin at cell-cell junction in the damaged heart tissue using immuno-histological analysis. However, the expression of VE-cadherin at cell-cell junctions was unclear in all images, therefore we evaluated the cell-cell junction by electron microscopy analysis. Thus, we added several electron microscopy images with several magnifications to the revised manuscript (new Figure 4A, 4B, 4C, 4D).

Comment 11: Fig. 4D-1

Chose another color than white for the dotted lines in this image.

Response 11: Following your suggestion, we changed the color of the dotted lines from white to yellow (page 24, line 1, and new Figure 5D-1).

Comment 12: Several images are very small and with low magnification. It is difficult to interpret the individual cells. For example in Fig. 4D-2; Fig4E.

Response 12: Thank you for your comments. For the initial submission, it was difficult for us to incorporate all the figures associated with examination 3 into only one page. Following your suggestion, we enlarged Figure 4D-2 and made the new Figure 5 (new Figure 5D-2). We separated Figure 4E, 4F, and 4G from Figure 4, and made them the new Figure 6 in the revised manuscript (new Figure 6).

Comment 13: Fig. 4D-2 show that not all GFP+ cells express Pdgfra. What kind of cells are GFP+/Pdgfrα-?

Response 13: In our other study investigating the effects of the HMGB1 fragment on bone marrow, we confirmed that HMGB1 led to the mobilization of not only BM-MSCs but also of endothelial progenitor cells (EPCs) from the bone marrow to the blood circulation. In the present study, we considered that the GFP+/PDGFRα+ cells were BM-MSCs as we had performed total GFP+-bone marrow transplantation. In contrast, we assumed that GFP+/ PDGFRα- cells were leukocytes such as M2 macrophages or BM-derived vascular endothelial cells such as EPCs.

Comment 14: Fig. 4F, G

It is not clear that GFP/PDGFRa and isolection/NG2 are coexpressed in certain cells, as none of the stainings are very specific. For example, the red color is more or less present I all cells. It is interesting to speculate that the cells differentiate into pericytes or endothelial cell, but more analyses are needed.

Response 14: In examination 3, we found that some GFP+/PDGFRα+ cells were present at the vessel component in the peri-infarction area after HMGB1 treatment. Because we used GFP-bone marrow-transplanted-rats, GFP+ cells were bone marrow-derived. Given this finding, we hypothesized that BM-MSCs would be mobilized to the damaged heart tissue by HMGB1, and that BM-MSCs might differentiate into vessel constituent cells.

In these Figures (old Figure 4F and 4G), PDGFRα is colored red. PDGFRα is a BM-MSC marker in the bone marrow, and is also a representative marker of mesenchymal cells such as vascular endothelial cells and pericytes. PDGFRα seems to be more highly expressed in the vessels, although other cells also seemed to be stained slightly red, as you mentioned. This is a limitation of immuno-histological analysis. We mentioned this point in the Discussion section (page 32, lines 8-13).

Comment 15: Video

Were the two samples identical from start, which they should have been. The HMBG1-sample has much more green cells both circulating and in the tissue when the video starts, compared to the sample that gets PBS.

Response 15: The purpose of the intravital imaging analysis was to investigate whether the recruitment of GFP+ cells to the damaged heart tissue could be enhanced by systemic administration of HMGB1. In the video of the HMGB1 group, it can be seen that GFP+ cells are mobilized to the damaged heart tissue and gradually increased in number after HMGB1 treatment. In contrast, in the video of the control (PBS) group, the recruitment of GFP+ cells to the damaged heart tissue was not enhanced after PBS injection. In addition, after intravital imaging, we also evaluated GFP+/PDGFRα+ cells at the peri-infarction area in the HMGB1 and PBS groups using immuno-histological analysis. However, as you mentioned, in the preoperative video of the control group, GFP+ cells seem to be present in lower numbers than that in the HMGB1 group.

Therefore, we excluded the movie of the PBS group from the revised manuscript, as the enhancement of GFP cell recruitment after HMGB1 injection can be observed in the video of the HMGB1 group.

Comment 16: Discussion, Page 31, line 3

A higher density of vessels was shown in the HMBG1 group, but it has not been shown that HMBG1 induce angiogenesis.

Response 16: The angiogenetic ability of HMGB1 in the ischemic tissue has already been reported in several models (references No. 11-13 and 24-26). In those studies, HMGB1 treatment induces VEGF over-expression in ischemic tissue, consequently leading to neovascularization in the damaged tissue. Similar to those reports, the present study showed enhancement of capillary density and VEGF-A expression in the damaged heart tissue after HMGB1 treatment. In addition, our study demonstrated that the mobilization of BM-MSCs to the peri-infarction area was enhanced by systemic administration of HMGB1, and that VEGF-A was expressed around the recruited BM-MSCs in the damaged heart tissue. Given previous lines of evidence and our findings, we considered that HMGB1 can lead to angiogenesis in the damaged heart tissue through VEGF-A via the paracrine effects of the recruited BM-MSCs. However, as you mentioned, the present study did not show that HMGB1 induces angiogenesis directly. To clarify the mechanism through which HMGB1 affects angiogenesis via VEGF-A, additional examinations using a model of blocked VEGF pathway will be required. We mentioned this information as a limitation of the present study in the revised manuscript (page 32, lines 4-8).
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